

Disruptive Technology and Emerging Trends in Novel Drug Delivery Systems: Integration of IoT for Precision Healthcare

Dineshkumar Munikrishnan *, Prabha R **, N. R. Dhineshabu ***, Kusumanjali S ****

*(Director, Head of Digital Omnichannel Analytics & InsightsBoehringer Ingelheim Pharmaceuticals Inc, Ridgefield CT, USA
Email: munidinesh@gmail.com)

** (Department of Computer Science and Engineering, T. John Institute of Technology, Bengaluru-560083, Karnataka, India
Email: research.prabha.r@gmail.com)

*** (Department of Electronics and Communication Engineering, T. John Institute of Technology, Bengaluru-560083,
Karnataka, India
Email: babudhinesh2009@gmail.com)

**** (Department of Computer Science and Engineering, T. John Institute of Technology, Bengaluru-560083, Karnataka, India
Email: kusumagowda0903@gmail.com)

Abstract:

Innovative Drug Delivery Systems (DDS) are transforming the administration of therapeutic agents, enhancing patient outcomes and overcoming the challenges associated with conventional methods. This white paper explores disruptive technologies and recent trends shaping the field of DDS. Key advancements include nanotechnology, microfluidics, biomaterials, 3D printing, implantable devices, wearable drug delivery, and digital health integration. These technologies enable targeted drug delivery, controlled release, personalized medicine, and combination therapies. The future of drug delivery holds immense potential for improving healthcare and offers exciting career opportunities for college students interested in this field.

Keywords — Novel drug delivery systems (NDS), Healthcare

I. INTRODUCTION

Drug delivery systems (DDS) have been a cornerstone of modern medicine, ensuring the efficient and effective delivery of therapeutic agents to their intended sites of action. Traditional methods, such as oral, intravenous, and topical administration, have served their purpose for many years. However, the limitations of these methods have spurred the development of novel DDS [1] that aim to revolutionize drug delivery and improve patient outcomes. This white paper will explore the disruptive technologies and latest trends shaping the landscape of novel drug delivery systems, providing insights for college students interested in this field [2].

BACKGROUND

The pursuit of more efficient and targeted drug delivery systems has been driven by several factors:

A. Improved Patient Compliance

Reduced dosing frequency: Traditional methods often necessitate multiple daily doses, which can be burdensome for patients and lead to missed doses or medication errors[3]. Novel DDS, such as extended-release formulations or implants, can reduce the frequency of dosing, making it easier for patients to adhere to their treatment regimens[4].

Improved convenience: Novel DDS can be designed to be more convenient for patients, such as wearable patches or oral disintegrating tablets. This can enhance patient satisfaction and increase adherence.

B. Enhanced Drug Bioavailability

Overcoming first-pass metabolism: Many drugs are subject to first-pass metabolism in the liver, which can significantly reduce their bioavailability[5]. Novel DDS, such as sustained-

release formulations or targeted delivery systems, can bypass the first-pass effect and increase the amount of drug reaching the systemic circulation.

Improving absorption: Some drugs may have poor absorption from the gastrointestinal tract. Novel DDS, such as nanoparticles or microfluidic devices, can enhance drug absorption by increasing solubility, permeability, or targeting specific tissues[6].

C. Reduced Side Effects

Minimizing off-target effects: Traditional drug delivery methods often result in systemic exposure, which can lead to adverse effects in non-target tissues. Novel DDS, such as targeted delivery systems or localized drug release, can reduce off-target effects by delivering drugs more precisely to their intended sites of action[7].

Reducing toxicity: By minimizing systemic exposure, novel DDS can also reduce the risk of drug toxicity, especially for drugs with narrow therapeutic windows.

D. Controlled Release

Maintaining therapeutic levels: Some drugs require sustained release over time to maintain therapeutic levels and avoid fluctuations[8]. Novel DDS, such as implants, pumps, or biodegradable matrices, can achieve controlled release profiles, ensuring optimal drug exposure and efficacy.

Reducing peak-trough effects: Traditional drug delivery methods can lead to significant fluctuations in drug levels, which can result in suboptimal therapeutic effects or adverse reactions. Controlled release DDS can help to minimize these peak-trough effects.

.DISRUPTIVE TECHNOLOGIES

Several disruptive technologies are at the forefront of novel drug delivery systems:

A. Nanotechnology

Unique properties: Nanoparticles possess unique properties, such as increased surface area-to-volume ratio, that can enhance drug delivery. These properties allow for improved drug

solubility, increased tissue penetration, and enhanced drug uptake by cells.

Drug solubility: Many drugs have limited solubility, which can hinder their absorption and efficacy. Nanoparticles can encapsulate drugs and increase their solubility, making them more bioavailable.

Tissue penetration: Nanoparticles can penetrate tissues and cells more effectively than larger drug molecules, allowing for targeted drug delivery to specific sites of action.

Drug protection: Nanoparticles can protect drugs from degradation by enzymes or other factors, extending their half-life and improving their therapeutic efficacy.

B. Microfluidics

Precise control: Microfluidic devices allow for precise control over the flow of fluids at the micro-scale, enabling the creation of complex drug formulations and controlled release profiles[17].

Drug formulations: Microfluidic devices can be used to create microparticles, droplets, or other drug formulations with specific properties, such as controlled release rates or targeting capabilities.

Controlled release: By manipulating the flow of fluids in microfluidic devices, it is possible to generate controlled release profiles, ensuring that drugs are released at a specific rate over time[9].

Diagnostic capabilities: Microfluidic devices can be integrated with diagnostic sensors or assays, allowing for real-time monitoring of drug delivery and patient response.

C. Biomaterials

Biocompatibility: Biodegradable and biocompatible materials are essential for creating drug delivery systems that are well-tolerated by the body. These materials can be designed to

degrade over time, releasing the drug gradually[10].

Controlled release: Biomaterials can be formulated to release drugs at a controlled rate, ensuring optimal drug exposure and minimizing side effects.

Tissue regeneration: Some biomaterials can stimulate tissue regeneration, making them suitable for applications such as wound healing or tissue engineering.

D. 3D Printing

Customization: 3D printing allows for the creation of customized drug delivery systems tailored to individual patient needs[11] This technology enables the production of complex geometries and precise control over drug release.

Complex geometries: 3D printing can be used to create intricate structures, such as implants or scaffolds, that can deliver drugs in a controlled manner or support tissue regeneration[12].

Precise control: By controlling the printing parameters, it is possible to achieve precise control over the distribution of drugs within the printed structures.

E. Implantable Devices

Continuous or on-demand delivery: Implantable devices can deliver drugs continuously or on demand, depending on the therapeutic needs.

Long-term drug delivery: These devices can provide long-term drug delivery, reducing the need for frequent dosing and improving patient compliance[13].

Therapeutic applications: Implantable devices have a wide range of therapeutic applications, including the treatment of chronic diseases, pain management, and hormone replacement.

LATEST TRENDS

A. Personalized Medicine

Tailored drug delivery: Advancements in genomics and personalized medicine are enabling the development of drug delivery systems that are

tailored to the specific genetic makeup and characteristics of individual patients[14].

Precision medicine: By understanding a patient's unique genetic profile, it is possible to select the most effective drugs and optimize their dosing to maximize therapeutic benefits and minimize side effects.

Personalized drug formulations: Novel DDS can be designed to deliver drugs in a manner that is specifically tailored to the patient's individual needs, such as using nanoparticles that target specific cell types or creating controlled release profiles that match the patient's metabolic rate.

B. Combination Therapies

Complex diseases: Many diseases, such as cancer and HIV, require multiple drugs to be administered simultaneously. Novel DDS can enable the simultaneous delivery of multiple drugs, improving therapeutic efficacy and reducing the need for multiple dosing regimens[14].

Synergistic effects: By combining drugs with complementary mechanisms of action, it is possible to achieve synergistic effects and enhance treatment outcomes.

Reduced side effects: Combination therapies can sometimes reduce side effects by targeting different pathways and minimizing off-target effects.

C. Drug-Device Combinations

Targeted drug delivery: The integration of drugs with medical devices, such as stents or implants, can enable targeted drug delivery to specific sites of action[15].

Improved patient outcomes: Drug-device combinations can offer improved patient outcomes by providing sustained drug release, reducing the need for frequent dosing, and enhancing the efficacy of therapeutic interventions.

Examples: Drug-eluting stents are used to deliver anti-proliferative drugs to prevent restenosis after coronary artery bypass surgery, and drug-releasing implants can be used to deliver growth factors for tissue regeneration.

D. Wearable Drug Delivery

Non-invasive delivery: Wearable devices, such as patches or bracelets, can deliver drugs non-invasively, eliminating the need for injections or oral administration.

Continuous delivery: These devices can deliver drugs continuously, ensuring consistent drug levels and improving patient compliance.

Applications: Wearable drug delivery systems are being developed for various applications, including pain management, hormone replacement, and nicotine replacement therapy.

E. Digital Health Integration

Real-time monitoring: Digital health technologies, such as sensors and mobile applications, can be used to monitor drug delivery in real-time, allowing for adjustments to the dosing regimen as needed.

Optimization of drug delivery: By collecting data on drug levels, patient response, and other factors, it is possible to optimize drug delivery and improve patient outcomes.

Remote monitoring: Digital health integration can enable remote monitoring of patients, reducing the need for frequent clinic visits and improving access to care.

REAL-TIME EXAMPLES OF PRACTICAL IMPLEMENTATION

A. Nanoparticle-Based Drug Delivery

Anticancer drugs: Nanoparticles offer a targeted approach to delivering anticancer drugs directly to tumor cells, reducing systemic toxicity and enhancing treatment effectiveness. For instance, liposomal nanoparticles are utilized to transport doxorubicin, a chemotherapy drug, specifically to cancer cells [21].

Vaccines: Nanoparticles can be used to create more effective vaccines by enhancing antigen presentation and immune response. For example, nanoparticle-based vaccines are being developed for diseases such as HIV, malaria, and cancer.

Gene therapy: Nanoparticles can be used to deliver genes to cells for gene therapy, offering potential treatments for genetic disorders. For

example, nanoparticles are being used to deliver genes that correct genetic defects in cystic fibrosis and muscular dystrophy.

B. Microfluidic Devices for Drug Screening

High-throughput screening: Microfluidic chips can be used to screen large numbers of drug candidates rapidly, accelerating the drug discovery process.

Miniaturization: Microfluidic devices allow for miniaturization of drug screening assays, reducing the amount of reagents required and improving efficiency.

Integration with other technologies: Microfluidic devices can be integrated with other technologies, such as mass spectrometry or fluorescence imaging, to provide comprehensive analysis of drug candidates.

C. 3D-Printed Drug Delivery Systems

Customization: 3D printing enables the development of personalized drug delivery systems designed to meet the specific needs of each patient, ensuring precise drug administration and maximizing therapeutic effectiveness. [18].

Controlled release: 3D-printed implants can be engineered to release medications at a controlled, steady rate, allowing for prolonged drug delivery and minimizing the need for repeated dosing.

Tissue engineering: 3D-printed scaffolds can be used to deliver drugs while simultaneously supporting tissue regeneration, offering potential treatments for conditions such as bone fractures or cartilage damage.

D. Implantable Drug Delivery Pumps

Insulin delivery: Implantable drug delivery pumps are commonly used to deliver insulin for patients with type 1 diabetes, providing continuous insulin therapy and improving glycemic control[19].

Chemotherapy delivery: Pumps can also be used to deliver chemotherapy drugs for cancer treatment, allowing for precise control of drug delivery and reducing systemic toxicity.

Other applications: Implantable pumps can be used to deliver a variety of drugs, including hormones, pain medications, and growth factors.

E. Wearable Drug Delivery Patches

Nicotine replacement therapy: Nicotine patches are a popular method for smoking cessation, providing a controlled release of nicotine to help reduce cravings and withdrawal symptoms.

Hormone delivery: Wearable patches can be used to deliver hormones, such as estrogen or testosterone, for hormone replacement therapy or contraception[20].

Pain management: Patches can also be used to deliver pain medications, providing localized relief for conditions such as chronic pain or arthritis.

THE FUTURE OF DRUG DELIVERY: A PROMISING FIELD FOR COLLEGE STUDENTS

A. Rapid Development: The field of drug delivery systems is experiencing rapid growth due to a confluence of factors:

Technological advancements: Breakthroughs in nanotechnology, microfluidics, biomaterials, 3D printing, and other technologies are providing new tools and techniques for drug delivery.

Unmet medical needs: Many diseases still lack effective treatments, and novel drug delivery systems offer the potential to address these unmet needs.

Patient demand: Patients are increasingly demanding more convenient, effective, and personalized drug delivery solutions.

B. Career Opportunities: Understanding the disruptive technologies and latest trends in drug delivery can open up a wide range of career opportunities for college students. Some potential career paths include:

Drug delivery research: Scientists and engineers can work on developing novel drug delivery systems, investigating new materials, and optimizing existing technologies[22].

Pharmaceutical development: Professionals in the pharmaceutical industry can apply their

knowledge of drug delivery to develop new drug formulations and improve existing products.

Biomedical engineering: Biomedical engineers can design and develop drug delivery devices and systems, focusing on areas such as implantable devices, wearable technology, and microfluidic systems[23].

Clinical research: Researchers can evaluate the efficacy and safety of novel drug delivery systems through clinical trials and studies.

Regulatory affairs: Professionals in regulatory affairs can help to ensure that novel drug delivery systems meet regulatory requirements and are approved for clinical use.

C. Revolutionizing Healthcare: The potential for novel drug delivery systems to revolutionize healthcare is immense. By addressing challenges such as patient compliance, drug bioavailability, and side effects, these systems can improve patient outcomes and enhance the quality of care. As the field continues to evolve, we can expect to see even more innovative and effective drug delivery solutions that will benefit patients around the world.

Table 1: The recent research findings of disruptive technology

S. No.	Author	Findings	Ref
1	Lisa Marinelli	This research explains the novel drug delivery system by encapsulating an antimicrobial peptide, FS10, in PEG-PLGA nanoparticles. When it is tested against <i>S. aureus</i> , the FS10-loaded nanoparticles demonstrated a lower minimum inhibitory concentration (MIC) (just above 128 µg/mL) than free FS10 (>256 µg/mL). This result suggests that the nanoparticles	23

		effectively shield FS10 from rapid degradation, enabling it to concentrate at the infection site. The findings highlight the potential of this nanoparticle-based method to enhance the stability and efficacy of hydrophilic therapeutics, paving the way for improved bacterial infection treatments.				non-target tissues. These systems outperform traditional methods by offering enhanced functionality, precision, automation, and effectiveness. Made from biocompatible and biodegradable nanomaterials or miniaturized devices, they incorporate multifunctional components with high viscoelasticity and extended circulation times, playing a vital role in disease management and treatment.	
2	Tsvetelina H Baryakova	Advanced drug delivery systems (DDSs) improve medication adherence by reducing dosing frequency, minimizing side effects, and enabling faster therapeutic effects. While current DDSs have shown positive outcomes, next-generation technologies—such as oral delivery of large biomolecules, automated dosing, and multi-dose capabilities—could transform treatment. However, technical and logistical challenges must be addressed to fully realize their potential.	24	4	Ju-Seop Kang	Therapeutic Drug Monitoring (TDM) research aims to optimize clinical outcomes by linking drug dosage, plasma concentration, and therapeutic effects. Starting with the initial prescription, TDM considers patient-specific factors such as age, weight, and organ function and carefully interprets concentration measurements with sampling times and patient responses. TDM ultimately ensures appropriate levels of complex medications for effective management across clinical situations.	26
3	Tobechukwu Christian Ezike	Recent drug delivery systems (DDS) utilize advanced technologies for targeted drug delivery, improving therapeutic effectiveness while minimizing effects on	25	5	Tarun Sahu	Nanotechnology, especially nanomedicine, greatly	27

		enhances healthcare by improving the safety and efficacy of treatments for toxic drugs like chemotherapy agents. It leverages cellular functions for targeted therapies and is applied across various medical fields. The review also suggests future innovations to increase treatment precision and reduce side effects in clinical practice.				opportunities to solve long-standing medical issues.	
6	Huan Zhang	Microfluidic technology improves nano drug delivery systems (NDDSs) by enhancing formulation control, consistency, and drug-loading capacity. Its success in mRNA vaccines for COVID-19 highlights scalability. The review covers the fundamentals, synthesis, industrial potential, and challenges of microfluidic NDDSs.	28	8	Jessica Mancilla-De-la-Cruz	The research highlights that 3D printing technology enables customized drug formulations for various dosage forms, including oral, topical, and implantable options. It categorizes seven 3D printing techniques, each suited for different drug types and materials. The review aims to guide professionals in advancing drug delivery applications using 3D printing.	30
7	Owen S Fenton	The research highlights advancements in biomaterials for drug delivery, advancing treatments for cancer, autoimmune diseases, and genome editing. It reviews design strategies, addresses challenges in RNA delivery, responsive materials, and immunomodulation, and identifies	29	9	Jingjing Gao	The research explores the alignment of current healthcare diagnostic practices with evidence-based guidelines, focusing on improving diagnostic accuracy and patient outcomes. It found that integrating advanced tools like machine learning models enhances accuracy. Tailored diagnostic approaches based on patient profiles led to better-targeted interventions and more efficient care. The study supports the use of advanced analytics to reduce misdiagnoses and recommends broader adoption of these technologies for	31

		better healthcare delivery.				resistance and relapse. The review explores various treatment strategies and technologies, including nanotechnology, that could enhance these therapies, highlighting the potential of combination approaches despite current challenges in implementation.	
10	Abhishek Soni	The research highlights that personalized medicine provides individualized treatments based on each person's genetic and molecular profile, leading to improved therapeutic effectiveness and fewer side effects. This approach also enables earlier disease detection, enhances understanding of patient conditions, and improves treatment selection. It discusses the historical context and future direction of personalized medicine, including its impact on customized drug delivery and regulatory aspects, demonstrating its significant influence on patient care and clinical research.	32				
				12	Jiahui He	Research shows that wearable transdermal drug delivery patches are a significant advancement in targeted medication delivery, avoiding challenges like gastrointestinal degradation and first-pass metabolism. Incorporating stimulus-responsive materials and electronics, these patches provide controlled dosing and timing, boosting bioavailability and patient compliance. This innovation enables precise, sustained drug release, enhancing therapeutic outcomes and expanding drug delivery technology options.	34
11	Yiling Wang	The research finds that combination therapies, which use multiple drugs to target different pathways, are more effective for treating breast cancer, particularly challenging types like metastatic and triple-negative breast cancer. Compared to monotherapy, combination treatments reduce long-term toxicity and address issues like therapy	33				
				13	Saniha Ajith	The study concludes that nanocarriers enable a targeted approach to chemotherapy, potentially reducing side effects and enhancing patient outcomes by focusing	35

		drug action on cancer cells while sparing healthy tissue. Nanocarriers like liposomes, polymeric micelles, and gold nanoparticles are examined for their synthesis, applications, benefits, and challenges, showing strong potential for targeted cancer therapy. However, further research is necessary to overcome clinical translation challenges.	
14	Jinyuan Zhang	The study highlights advances in wearable glucose monitors and implantable insulin delivery for improved diabetes management. Innovations like sensors in skin patches, eyewear, and fabrics enable real-time, noninvasive glucose monitoring, integrating with insulin devices for automated, closed-loop care. This approach promises precise, responsive diabetes management, addressing limitations of traditional methods while recognizing ongoing challenges and unmet needs to drive further enhancements in patient outcomes.	36

II. CONCLUSIONS

Novel drug delivery systems are undergoing rapid development, driven by technological advancements

and a desire to improve patient outcomes. By understanding the disruptive technologies and latest trends in this field, college students can gain valuable insights into the future of drug delivery and explore potential career opportunities. As the field continues to evolve, the potential for novel DDS to revolutionize healthcare is immense.

REFERENCES

- [1] Q. Chen, Z. Yang, H. Liu, J. Man, A. O. Oladejo, S. Ibrahim, S. Wang, and B. Hao, "Novel drug delivery systems: An overview of advancements," *Pharmaceutics*, 16(5), pp. 674, 2024.
- [2] T. C. Ezike, U. S. Okpal, U. L. Onoja, C. P. Nwike, E. C. Ezeako, O. J. Okpara, C. C. Okoroafor, S. C. Eze, O. L. Kalu, E. C. Odoh, U. G. Nwadike, J. O. Ogbodo, B. U. Umeh, E. C. Ossai, and B. C. Nwanguma "Advances in drug delivery systems, challenges and future directions," *Heliyon*, Vol. 9, No. 6, pp. e17488, Jun 2023.
- [3] Q. Chen, Z. Yang, H. Liu, J. Man, A. O. Oladejo, S. Ibrahim, S. Wang, and B. Hao, "Novel Drug Delivery Systems: An Important Direction for Drug Innovation Research and Development," *Pharmaceutics*. Vol. 16 No. 5, pp. 674, May 2024.
- [4] A. S. Raikar, P. Kumar, G. V. S. Raikar, and S. N. Somnache, "Advances and challenges in IoT-based smart drug delivery systems: a comprehensive review," *App. System Innovation*, 6(4), pp. 62, 2023.
- [5] G. Tiwari, R. Tiwari, B. Sriwastawa, L. Bhati, S. Pandey, P. Pandey, and S. K. Bannerjee, "Drug delivery systems: An updated review," *Intenat. J. Pharm. Invest.*, Vol. 21, No. 2, 2012.
- [6] S. Mitragotri, P. A. Burke, and R. Langer, "Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies," *Nature reviews Drug discovery*, vol. 13, No. 9, 655-67, 2014.
- [7] J. Gao, J. M. Karp, R. Langer, and N. Joshi, "The future of drug delivery," *Chem. Mater.*, vol. 35, No. 2, pp. 359-363, 2023.
- [8] K. Park, "Controlled drug delivery systems: past forward and future back," *J. Controlled Release*, vol. 190, pp. 3-8, 2014.
- [9] D. A. Lamprou, "Emerging technologies for diagnostics and drug delivery in the fight against COVID-19 and other pandemics," *Expert review of medical devices*, vol. 17, No. 10, pp. 1007-1012, 2020.
- [10] J. Wang, Y. Zhang, N. H. Aghda, A. R. Pillai, R. Thakkar, A. Nokhodchi, and M. Maniruzzaman, "Emerging 3D printing technologies for drug delivery devices: Current status and future perspective," *Adv. Drug Delivery Rev.*, vol. 174, pp. 294-316, 2021.
- [11] S. Jacob, A. B. Nair, V. Patel, and J. Shah, "3D printing technologies: recent development and emerging applications in various drug delivery systems," *AAPS Pharm. Sci. Tech.*, vol. 21, pp. 1-16, 2020.
- [12] Y. S., Zhang, and A. Khademhosseini, "Advances in engineering hydrogels," *Sci.*, vol. 356, No. 6337, pp. eaaf3627, 2017
- [13] J. Y. Chien, and R. J. Ho, "Drug delivery trends in clinical trials and translational medicine," *J. Pharmaceutical Sci.*, vol. 97, No. 7, pp. 2543-2547, 2008.
- [14] S. Mura, J. Nicolas, and P. Couvreur "Stimuli-responsive nanocarriers for drug delivery," *Nature materials*, vol. 12, No. 11, pp. 991-1003, 2013.
- [15] D. F., Emerich, and C. G. Thanos, "Targeted nanoparticle-based drug delivery and diagnosis," *J. Drug Targeting*, vol. 15, No. 3, pp. 163-183, 2007.
- [16] S. Damiati, U. B. Kompella, S. A. Damiati, and R. Kodzius, "Microfluidic devices for drug delivery systems and drug screening". *Genes*, Vol. 9, No. 2, pp. 103, 2018.
- [17] I. Bácskay, Z. Ujhelyi, P. Fehér, and P. Arany, "The evolution of the 3D-printed drug delivery systems: a review," *Pharmaceutics*, vol. 14, No. 7, pp. 1312, 2022.

- [18] M. Danckwerts, and A. Fassihi, "Implantable controlled release drug delivery systems: a review," *Drug Devel. and Ind. Phar.*, 17(11), 1465-1502, 1991.
- [19] A. Kar, N. Ahamad, M. Dewani, L. Awasthi, R. Patil, and R. Banerjee, "Wearable and implantable devices for drug delivery: Applications and challenges," *Biomater.*, vol. 283, pp. 121435, 2022.
- [20] C. L. Ventola, "Progress in nanomedicine: approved and investigational nanodrugs," *Pharmacy and Therapeutics*, vol. 42, No. 12, pp. 742, 2017.
- [21] J. Gao, J. M. Karp, R. Langer, and N. Joshi, "The future of drug delivery," *Chem. of Mater.*, vol. 35, No. 2, pp. 359-363, 2023.
- [22] S. Mitragotri, "Devices for overcoming biological barriers: the use of physical forces to disrupt the barriers," *Adv. Drug Deliv. Rev.*, Vol. 65, No. 1, pp. 100-103, 2013.
- [23] L. Marinelli, M. Ciulla, J. A S Ritsema, C. F van Nostrum, I. Cacciatore, M. Pia Dimmito, F. Palmerio, G. Orlando, I. Robuffo, R. Grande, V. Puca, A. Di Stefano Preparation, Characterization, and Biological Evaluation of a Hydrophilic Peptide Loaded on PEG-PLGA Nanoparticles, *Pharmaceutics*, 2022 Aug 29;14(9):1821
- [24] Tsvetelina H Baryakova, Brett H Pogostin, Robert Langer, Kevin J McHugh Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems *Nat Rev Drug Discov.* 2023 Mar 27;22(5):387-409.
- [25] Tobechukwu Christian Ezike, Ugochukwu Solomon Okpala, Ufedo Lovet Onoja, Chinenye Princess Nwike, Emmanuel Chimeh Ezeako, Osinachi Juliet Okpara, Charles Chinkwere Okoroafor, Shadrach Chinecherem Eze, Onyinyechi Loveth Kalu, Evaristus Chinonso Odoh, Ugochukwu Gideon Nwadike, John Onyebuchi Ogbodo, Bravo Udochukwu Umeh, Emmanuel Chekwube Ossai, Bennett Chima, Advances in drug delivery systems, challenges and future directions, *Nwanguma, Heliyon* . 2023 Jun 24;9(6):e17488.
- [26] Ju-Seop Kang, Min-Ho Lee Overview of Therapeutic Drug Monitoring *Korean J Intern Med* . 2009 Mar 6;24(1):1-10
- [27] Tarun Sahu, Yashwant Kumar Ratre, Sushma Chauhan, L.V.K.S. Bhaskar, Maya P. Nair, Henu Kumar Verma, Nanotechnology based drug delivery system: Current strategies and emerging therapeutic potential for medical science, *Journal of Drug Delivery Science and Technology*, Volume 63, June 2021, 102487
- [28] Huan Zhang, Jie Yang, Rongze Sun, Songren Han, Zhaogang Yang, Lesheng Teng Microfluidics for nano-drug delivery systems: From fundamentals to industrialization, *Acta Pharmaceutica Sinica B*, Volume 13, Issue 8, August 2023, Pages 3277-3299
- [29] Owen S Fenton, Katy N Olafson, Padmini S Pillai, Michael J Mitchell, Robert Langer, *Advances in Biomaterials for Drug Delivery*, *Adv Mater.* 2018 May 7:e1705328.
- [30] Jessica Mancilla-De-la-Cruz, Marisela Rodriguez-Salvador, Jia An, Chee Kai Chua, Three-Dimensional Printing Technologies for Drug Delivery Applications: Processes, Materials, and Effects, *Int J Bioprint* . 2022 Oct 20;8(4):622.
- [31] Jingjing Gao, Jeffrey M Karp, Robert Langer, Nitin Joshi, The Future of Drug Delivery, *Chem Mater.* 2023 Jan 24;35(2):359-363.
- [32] Abhishek Soni, Kuppusamy Gowthamarajan, Arun Radhakrishnan, Personalized Medicine and Customized Drug Delivery Systems: The New Trend of Drug Delivery and Disease Management, *Int J Pharm Compd.* 2018 Mar-Apr;22(2):108-121.
- [33] Yiling Wang, Audrey Minden Current Molecular Combination Therapies Used for the Treatment of Breast Cancer *Int J Mol Sci.* 2022 Sep 20;23(19):11046
- [34] Jiahui He, Yuyue Zhang, Xinge Yu, Chenjie Xu, Wearable patches for transdermal drug delivery, *Acta Pharm Sin B.* 2023 May 15;13(6):2298-2309.
- [35] Saniha Ajith, Fares Almomani, Abdelbary Elhissi, Ghaleb A Hussein, Nanoparticle-based materials in anticancer drug delivery: Current and future prospects, *Heliyon* . 2023 Oct 20;9(11):e21227.
- [36] Jinyuan Zhang, Jian Xu, Jongcheon Lim, James K Nolan, Hyowon Lee, Chi Hwan Lee Wearable Glucose Monitoring and Implantable Drug Delivery Systems for Diabetes Management, *Adv Healthc Mater.* 2021 Sep;10(17):e2100194.